8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Feb 23, 2026·SEC
ORIC Pharmaceuticals, Inc.(ORIC)Earnings, Financials & Key Ratios
ORIC•NASDAQ
Price updated Jun 19, 2026
AboutORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$142M
- Net Income-$129M-1.3%
- EPS (Diluted)-1.47+19.7%
- ROE-41.27%+24.6%
ORIC Key Insights
ORIC Pharmaceuticals, Inc. (ORIC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 11.9% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 25.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ORIC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ORIC Price & Volume
ORIC Pharmaceuticals, Inc. (ORIC) stock price & volume — 10-year historical chart
Loading chart...
ORIC Growth Metrics
ORIC Pharmaceuticals, Inc. (ORIC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM22.99%
Return on Capital
10 Years-48.98%
5 Years-42.79%
3 Years-50.34%
Last Year-44.7%
ORIC Recent Earnings
ORIC Pharmaceuticals, Inc. (ORIC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.34-6.0%
$0.32
Rev
—
—
Q1 2026
Feb 23, 2026Metric
Actual
Est
EPS
$0.30+11.8%
$0.34
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.33+19.5%
$0.41
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.47-2.2%
$0.46
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.34vs $0.32-6.0% | — |
| Q1 2026 | Feb 23, 2026 | $0.30vs $0.34+11.8% | — |
| Q4 2025 | Nov 13, 2025 | $0.33vs $0.41+19.5% | — |
| Q3 2025 | Aug 12, 2025 | $0.47vs $0.46-2.2% | — |
Based on last 12 quarters of dataView full earnings history →
ORIC Peer Comparison
ORIC Pharmaceuticals, Inc. (ORIC) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 PMVP | 60.26M | 1.13 | -0.76 | -68.98% | 0.01 | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare ORIC vs Peers
ORIC Pharmaceuticals, Inc. (ORIC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ORIC Income Statement
ORIC Pharmaceuticals, Inc. (ORIC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 900K | 900K | 1M | 0 | 0 | 0 | 1.03M | 1.11M | 1.22M | 320K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -900K▲ 0% | -900K▲ 0.0% | -1M▼ 11.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -1.03M▲ 0% | -1.11M▼ 7.3% | -1.22M▼ 10.2% | -320K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | 0% | -11.11% | 100% | - | - | - | -7.27% | -10.21% | - |
Operating Expenses | 21.64M | 22.37M | 27.57M | 74.19M | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M | 149.59M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 2.52M | 3.35M | 4.72M | 13.42M | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M | 33.29M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 19.13M | 19.03M | 22.84M | 60.76M | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M | 116.61M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 233K | 0 | 0 | 0 | 5M | -1.03M | -1.11M | -1.22M | -320K |
Operating Income | -22.54M▲ 0% | -22.37M▲ 0.8% | -28.57M▼ 27.7% | -74.19M▼ 159.7% | -78.87M▼ 6.3% | -91.77M▼ 16.4% | -110.78M▼ 20.7% | -142.9M▼ 29.0% | -143M▼ 0.1% | -149.91M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 0.75% | -27.71% | -159.67% | -6.32% | -16.35% | -20.72% | -28.99% | -0.08% | - |
EBITDA | -21.64M | -21.47M | -27.57M | -73.22M | -77.97M | -90.8M | -109.75M | -141.79M | -141.78M | -148.72M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | 0.79% | -28.4% | -165.57% | -6.5% | -16.45% | -20.87% | -29.19% | 0% | -2.23% |
D&A (Non-Cash Add-back) | 900K | 900K | 1M | 970K | 897K | 966K | 1.03M | 1.11M | 1.22M | 1.19M |
EBIT | -22.54M | -22.37M | -26.88M | -49.34M | -78.87M | -86.77M | -110.78M | -127.85M | -129.47M | -141.78M |
Net Interest Income | 0 | 775K | 1.4M | 306K | 141K | 0 | 10.08M | 0 | 0 | 0 |
Interest Income | 251K | 775K | 1.4M | 306K | 141K | 2.65M | 10.08M | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 2.65M | 0 | 0 | 0 | 0 |
Other Income/Expense | 512K | 1.01M | 1.69M | 483K | 156K | 2.65M | 10.08M | 15.05M | 13.54M | 14.69M |
Pretax Income | -22.03M▲ 0% | -21.36M▲ 3.0% | -26.88M▼ 25.8% | -73.7M▼ 174.2% | -78.72M▼ 6.8% | -89.12M▼ 13.2% | -100.7M▼ 13.0% | -127.85M▼ 27.0% | -129.47M▼ 1.3% | -135.21M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -22.03M▲ 0% | -21.36M▲ 3.0% | -26.88M▼ 25.8% | -73.7M▼ 174.2% | -78.72M▼ 6.8% | -89.12M▼ 13.2% | -100.7M▼ 13.0% | -127.85M▼ 27.0% | -129.47M▼ 1.3% | -135.21M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | 3.02% | -25.84% | -174.16% | -6.8% | -13.22% | -12.99% | -26.96% | -1.27% | -1.77% |
Net Income (Continuing) | -22.03M | -21.36M | -26.88M | -73.7M | -78.72M | -89.12M | -100.7M | -127.85M | -129.47M | -135.21M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -15.62▲ 0% | -12.32▲ 21.1% | -1.40▲ 88.6% | -3.36▼ 140.0% | -2.07▲ 38.4% | -2.25▼ 8.7% | -1.96▲ 12.9% | -1.83▲ 6.6% | -1.47▲ 19.7% | -1.28▲ 0% |
EPS Growth % | - | 21.13% | 88.64% | -140% | 38.39% | -8.7% | 12.89% | 6.63% | 19.67% | 22.99% |
EPS (Basic) | -15.62 | -12.32 | -1.40 | -3.36 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | - |
Diluted Shares Outstanding | 1.41M | 1.73M | 19.14M | 21.94M | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M | 105.47M |
Basic Shares Outstanding | 1.41M | 1.73M | 1.9M | 21.94M | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M | 105.47M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ORIC Balance Sheet
ORIC Pharmaceuticals, Inc. (ORIC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 26.61M | 43.72M | 90M | 296.7M | 240.52M | 210.46M | 212.6M | 262.25M | 288.47M | 290.23M |
Cash & Short-Term Investments | 25.82M | 42.64M | 89.16M | 293.6M | 236.98M | 206.27M | 208.19M | 255.96M | 281.49M | 281.93M |
Cash Only | 25.82M | 42.64M | 89.16M | 78.45M | 226.01M | 66.84M | 23.38M | 59.41M | 45.67M | 56.4M |
Short-Term Investments | 0 | 0 | 0 | 215.15M | 10.97M | 139.43M | 184.8M | 196.55M | 235.82M | 225.54M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 840K | 0 | 0 | 4.18M | 4.41M | 6.29M | 6.98M | 8.3M |
Total Non-Current Assets | 3.42M | 3.01M | 4.09M | 2.3M | 58.12M | 39.9M | 42.09M | 11.89M | 122.54M | 146.53M |
Property, Plant & Equipment | 2.9M | 2.51M | 2.24M | 1.98M | 2.41M | 14.25M | 12.01M | 2.92M | 9.07M | 2.15M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 43.39M | 22.42M | 27.34M | 0 | 111.25M | 420.16M |
Other Non-Current Assets | 513K | 496K | 1.85M | 319K | 12.32M | 49K | 61K | 8.97M | 98K | 6.6M |
Total Assets | 30.02M▲ 0% | 46.73M▲ 55.7% | 94.09M▲ 101.3% | 299M▲ 217.8% | 298.64M▼ 0.1% | 250.36M▼ 16.2% | 254.69M▲ 1.7% | 274.14M▲ 7.6% | 411M▲ 49.9% | 436.76M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 55.65% | 101.34% | 217.77% | -0.12% | -16.17% | 1.73% | 7.64% | 49.92% | 177.97% |
Total Current Liabilities | 2.61M | 2.6M | 5.35M | 9M | 15.15M | 15.39M | 20.46M | 24.85M | 20.42M | 17.77M |
Accounts Payable | 940K | 446K | 152K | 757K | 1.89M | 1.32M | 944K | 1.55M | 3.82M | 2.9M |
Days Payables Outstanding | 381.22 | 180.88 | 55.48 | - | - | - | 333.88 | 510.41 | 1.14K | 3.64K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.66M | 2.75M | 0 | 3.33M | 0 |
Deferred Revenue (Current) | 388K | 438K | 495K | 546K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 448K | 115K | 2.82M | 0 | 4.8M | 6.09M | 10.23M | 7.65M | 13.26M | 14.88M |
Current Ratio | 10.20x | 16.84x | 16.81x | 32.96x | 15.87x | 13.68x | 10.39x | 10.56x | 14.13x | 16.33x |
Quick Ratio | 10.20x | 16.84x | 16.81x | 32.96x | 15.87x | 13.68x | 10.39x | 10.56x | 14.13x | 16.33x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 1.69M | 108.56M | 765K | 219K | 10.52M | 12.62M | 10.14M | 6.17M | 6.22M | 3.43M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.11M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 9.44M | 7.46M | 0 | 4.11M | 4.11M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 3.18M | 2.68M | 0 | 2.11M | 2.11M |
Other Non-Current Liabilities | 0 | 107.31M | 0 | 219K | 10.52M | 0 | 0 | 6.17M | -4.11M | 3.43M |
Total Liabilities | 4.3M | 111.16M | 6.12M | 9.22M | 25.67M | 28.01M | 30.6M | 31.02M | 26.64M | 21.2M |
Total Debt | 0 | 0 | 0 | 0 | 1.93M | 12.1M | 10.21M | 3.18M | 11.55M | 0 |
Net Debt | -25.82M | -42.64M | -89.16M | -78.45M | -224.08M | -54.74M | -13.17M | -56.22M | -34.12M | -56.4M |
Debt / Equity | - | - | - | - | 0.01x | 0.05x | 0.05x | 0.01x | 0.03x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.38x |
Interest Coverage | - | - | - | - | - | -32.80x | - | - | - | - |
Total Equity | 25.73M▲ 0% | -64.43M▼ 350.4% | 87.97M▲ 236.6% | 289.78M▲ 229.4% | 272.98M▼ 5.8% | 222.35M▼ 18.5% | 224.09M▲ 0.8% | 243.12M▲ 8.5% | 384.36M▲ 58.1% | 415.56M▲ 0% |
Equity Growth % | - | -350.43% | 236.55% | 229.39% | -5.8% | -18.55% | 0.78% | 8.49% | 58.09% | 202.86% |
Book Value per Share | 18.24 | -37.15 | 4.60 | 13.21 | 7.19 | 5.61 | 4.36 | 3.49 | 4.38 | 3.94 |
Total Shareholders' Equity | 25.73M | -64.43M | 87.97M | 289.78M | 272.98M | 222.35M | 224.09M | 243.12M | 384.36M | 415.56M |
Common Stock | 1K | 1K | 1K | 4K | 4K | 5K | 6K | 7K | 11K | 11K |
Retained Earnings | -44.44M | -65.81M | -92.69M | -166.39M | -245.11M | -334.23M | -434.93M | -562.77M | -692.24M | -728.01M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -2.58M | 0 | -31K | -103K | -1.29M | 258K | 379K | 786K | -290K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORIC Cash Flow Statement
ORIC Pharmaceuticals, Inc. (ORIC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.83M | -20.68M | -23.53M | -45.27M | -59.54M | -75.14M | -85.69M | -112.66M | -113.37M | -110.88M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | 0.72% | -13.78% | -92.36% | -31.53% | -26.2% | -14.03% | -31.48% | -0.63% | 13.32% |
Net Income | -22.03M | -21.36M | -26.88M | -73.7M | -78.72M | -89.12M | -100.7M | -127.85M | -129.47M | -135.21M |
Depreciation & Amortization | 900K | 903K | 1.03M | 970K | 897K | 966K | 1.03M | 1.11M | 1.22M | 1.19M |
Stock-Based Compensation | 217 | 469K | 1.09M | 5.28M | 12.85M | 14.46M | 15.23M | 20.21M | 0 | 25.38M |
Deferred Taxes | 0 | 0 | 0 | 299K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2M | 15K | 8K | 19.84M | 1.35M | -1M | -6.15M | -8.1M | 20.34M | -1.26M |
Working Capital Changes | 95K | -707K | 1.22M | 2.04M | 4.07M | -445K | 4.9M | 1.97M | -5.46M | -974K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 6K | -410K | 986K | 4.3M | 2.93M | -1.48M | 0 | 1.82M | -7.25M | -448K |
Cash from Investing | -292K | -508K | -768K | -215.96M | 158.44M | -109.25M | -43.4M | 22.14M | -148.03M | -188.46M |
Capital Expenditures | -486K | -525K | -768K | -667K | -939K | -2.08M | -849K | -1.19M | -712K | -550K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 1.38M | 2.08M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 194K | 17K | 0 | 193K | -1.38M | -2.08M | 0 | 0 | 0 | 223K |
Cash from Financing | 260K | 38.01M | 70.82M | 250.51M | 49.13M | 25.23M | 85.66M | 126.55M | 247.66M | 306.39M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 260K | 37.93M | 70.79M | 271.31M | 50M | 25M | 85M | 125M | 247.66M | 308M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 79K | 32K | -20.79M | -866K | 225K | 658K | 1.55M | 0 | -1.61M |
Net Change in Cash | -20.86M▲ 0% | 16.82M▲ 180.6% | 46.52M▲ 176.6% | -10.71M▼ 123.0% | 148.03M▲ 1481.8% | -159.17M▼ 207.5% | -43.43M▲ 72.7% | 36.02M▲ 182.9% | -13.74M▼ 138.1% | 7.06M▲ 0% |
Free Cash Flow | -21.32M▲ 0% | -21.21M▲ 0.5% | -24.3M▼ 14.6% | -45.94M▼ 89.0% | -60.48M▼ 31.7% | -77.22M▼ 27.7% | -86.54M▼ 12.1% | -113.85M▼ 31.6% | -114.08M▼ 0.2% | -111.36M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | 0.52% | -14.58% | -89.03% | -31.66% | -27.68% | -12.06% | -31.56% | -0.2% | 4.5% |
FCF per Share | -15.11 | -12.23 | -1.27 | -2.09 | -1.59 | -1.95 | -1.68 | -1.63 | -1.30 | -1.06 |
FCF Conversion (FCF/Net Income) | 0.95x | 0.97x | 0.88x | 0.61x | 0.76x | 0.84x | 0.85x | 0.88x | 0.88x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORIC Key Ratios
ORIC Pharmaceuticals, Inc. (ORIC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -228.33% | -39.02% | -27.98% | -35.99% | -45.11% | -54.73% | -41.27% | -35.33% |
Return on Invested Capital (ROIC) | - | - | -52.95% | -45.46% | -63.58% | -43.9% | -53.88% | -39.93% | -34.03% |
Debt / Equity | - | - | - | 0.01x | 0.05x | 0.05x | 0.01x | 0.03x | 0.00x |
Interest Coverage | - | - | - | - | -32.80x | - | - | - | - |
FCF Conversion | 0.97x | 0.88x | 0.61x | 0.76x | 0.84x | 0.85x | 0.88x | 0.88x | 0.82x |
Related:ORIC Dividend History·ORIC Revenue History·ORIC Price History·ORIC P/E History·ORIC Financial Ratios·ORIC Institutional Holders
ORIC SEC Filings & Documents
ORIC Pharmaceuticals, Inc. (ORIC) SEC filings — annual & quarterly reports (10-K, 10-Q)
ORIC Frequently Asked Questions
ORIC Pharmaceuticals, Inc. (ORIC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ORIC Pharmaceuticals, Inc. (ORIC) grew revenue by 0.0% over the past year. Growth has been modest.
ORIC Pharmaceuticals, Inc. (ORIC) reported a net loss of $135.2M for fiscal year 2025.
Dividend & Returns
ORIC Pharmaceuticals, Inc. (ORIC) has a return on equity (ROE) of -41.3%. Negative ROE indicates the company is unprofitable.
ORIC Pharmaceuticals, Inc. (ORIC) had negative free cash flow of $111.4M in fiscal year 2025, likely due to heavy capital investments.